Literature DB >> 22010788

Levels of asymmetric dimethylarginine throughout normal pregnancy and in pregnancies complicated with preeclampsia or had a small for gestational age baby.

Demetrios Rizos1, Makarios Eleftheriades, Emmanuel Batakis, Myrto Rizou, Alexander Haliassos, Demetrios Hassiakos, Demetrios Botsis.   

Abstract

OBJECTIVE: The aim of this study was to investigate maternal asymmetric dimethylarginine (ADMA) concentrations at the three trimesters of pregnancy in uncomplicated pregnancies and in women who developed preeclampsia or had small for gestational age infants (SGA) without preeclampsia.
METHODS: ADMA concentrations were retrospectively determined in the first, second and third trimester of pregnancy in 41 uncomplicated pregnancies, 10 pregnancies complicated with preeclampsia and 14 pregnancies that delivered a SGA baby. ADMA was measured with an ELISA kit.
RESULTS: Mean (±SD) concentrations of ADMA (µmol/L) in uncomplicated l pregnancies were: 0.51 ± 0.14; 0.52 ± 0.13; 0.58 ± 0.16 in the three trimesters, respectively. ADMA concentrations in SGA pregnancies were significantly lower in each trimester compared to uncomplicated pregnancies: (0.40 ± 0.10, p = 0.005 1st trim; 0.42 ± 0.10, p = 0.007 2nd trim; 0.45 ± 0.10, p = 0.007 3rd trim). Although pregnancies that developed preeclampsia had higher ADMA concentration in all trimesters compared to uncomplicated pregnancies (0.58 ± 0.10; 0.63 ± 0.14; 0.68 ± 0.11), the difference was statistically significant only in the 2nd trimester (p = 0.02).
CONCLUSIONS: Maternal serum ADMA concentration tends to increase during normal pregnancy. Pregnancies with SGA infants had significantly lower ADMA levels in all trimesters of pregnancy. ADMA concentrations in the 2nd trimester was significantly elevated in pregnancies that later developed preeclampsia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22010788     DOI: 10.3109/14767058.2011.632037

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  7 in total

1.  Maternal cardiovascular and endothelial function from first trimester to postpartum.

Authors:  Vassiliki Kolovetsiou-Kreiner; Manfred Georg Moertl; Ilona Papousek; Karin Schmid-Zalaudek; Uwe Lang; Dietmar Schlembach; Mila Cervar-Zivkovic; Helmut Karl Lackner
Journal:  PLoS One       Date:  2018-05-21       Impact factor: 3.240

Review 2.  Clinical Presentation of Preeclampsia and the Diagnostic Value of Proteins and Their Methylation Products as Biomarkers in Pregnant Women with Preeclampsia and Their Newborns.

Authors:  Maria Portelli; Byron Baron
Journal:  J Pregnancy       Date:  2018-06-28

Review 3.  The Role of Nitric Oxide, ADMA, and Homocysteine in The Etiopathogenesis of Preeclampsia-Review.

Authors:  Weronika Dymara-Konopka; Marzena Laskowska
Journal:  Int J Mol Sci       Date:  2019-06-05       Impact factor: 5.923

4.  A comparison of maternal serum levels of endothelial nitric oxide synthase, asymmetric dimethylarginine, and homocysteine in normal and preeclamptic pregnancies.

Authors:  Marzena Laskowska; Katarzyna Laskowska; Mahfoz Terbosh; Jan Oleszczuk
Journal:  Med Sci Monit       Date:  2013-06-05

5.  Is the serum l-arginine level during early pregnancy a predictor of pregnancy-induced hypertension?

Authors:  Jingwen Wang; Tomomi Kotani; Hiroyuki Tsuda; Yukio Mano; Seiji Sumigama; Hua Li; Koji Komatsu; Rika Miki; Ei Maruta; Yoshimitsu Niwa; Takashi Mitsui; Shigeru Yoshida; Mamoru Yamashita; Koji Tamakoshi; Fumitaka Kikkawa
Journal:  J Clin Biochem Nutr       Date:  2015-06-04       Impact factor: 3.114

6.  Circulating asymmetric dimethylarginine and the risk of preeclampsia: a meta-analysis based on 1338 participants.

Authors:  Jing Yuan; Xinguo Wang; Yudou Xie; Yuzhi Wang; Lei Dong; Hong Li; Tongyu Zhu
Journal:  Oncotarget       Date:  2017-07-04

Review 7.  Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm?

Authors:  Asif Ahmed; Wenda Ramma
Journal:  Br J Pharmacol       Date:  2015-03       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.